- Poster presentation
- Open Access
Economic argument for citrate haemofiltration
© Patterson et al. 2011
- Published: 1 March 2011
- Cost Saving
- Cost Analysis
- Potential Cost
Regional citrate anticoagulation is associated with increased mean filter life and greater completion of scheduled filter life compared with heparin . Studies report mean filter lifespans of 44 hours  and that 80% of patients reach 72 hours . The potential cost saving from this reduced filter kit purchase is only realised if the treatment is stopped due to filter clotting and needs to be recommenced. In order to identify this we set out to evaluate the filter life and stopping reason for CVVHF treatment in general critically ill patients.
One hundred sequential patients receiving CVVHF were identified. For each patient, the number of treatments, filter life and reason for stopping treatment were recorded. A subset of treatments in which stopping was due to filter clotting and therapy resumed was identified. These were then analysed to see how many filtration sets could be saved if the filter life was 44 hours . Sensitivity analysis was performed based on a 50% change in filter life improvement.
Treatments by stopping reason
Duration (median) (hours)
Prolonged filter life associated with citrate CVVHF leads to a potential saving of €4.01/treatment-hour. This information is of benefit when considering the business case for introducing citrate continuous venovenous haemofiltration.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.